Cancers,
Journal Year:
2025,
Volume and Issue:
17(4), P. 701 - 701
Published: Feb. 19, 2025
Glioblastoma
multiforme
(GBM)
is
a
highly
malignant
brain
tumor
that
has
bleak
outlook
despite
existing
treatments
such
as
surgery,
radiation,
and
chemotherapy.
The
utilization
of
nanoparticles
for
drug
delivery
presents
promising
method
by
which
to
improve
the
effectiveness
treatment
while
reducing
harmful
effects
on
entire
body.
This
review
examines
application
in
GBM,
focusing
different
types
nanoparticles,
including
lipid-based,
polymeric,
metallic,
those
under
development.
Every
variety
analyzed
its
distinct
characteristics
therapeutic
capacity.
Lipid-based
liposomes
solid
lipid
enhance
transport
medicines
are
not
soluble
water
have
shown
considerable
potential
preclinical
investigations.
Polymeric
benefits
terms
controlled
release
targeted
distribution,
whereas
metallic
both
therapy
imaging.
In
current
we
would
like
emphasize
ways
medicine
delivery,
specifically
enhancing
penetration
blood-brain
barrier
(BBB),
targeting
tumors,
enabling
release.
Additionally,
also
discuss
clinical
discoveries,
highlighting
achievements
obstacles
process
converting
these
technologies
into
effective
GBM.
study
offers
thorough
examination
present
status
prospects
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Nov. 12, 2024
Esophageal
cancer
(EC)
is
a
malignancy
with
high
incidence
and
poor
prognosis,
significantly
influenced
by
dysbiosis
in
the
esophageal,
oral,
gut
microbiota.
This
review
provides
an
overview
of
roles
microbiota
EC
pathogenesis,
emphasizing
their
impact
on
tumor
progression,
drug
efficacy,
biomarker
discovery,
therapeutic
interventions.
Lifestyle
factors
like
smoking,
alcohol
consumption,
betel
nut
use
are
major
contributors
to
development.
Recent
studies
utilizing
advanced
sequencing
have
revealed
complex
interactions
between
EC,
oral
pathogens
such
as
Porphyromonas
gingivalis
Fusobacterium
nucleatum
promoting
inflammation
suppressing
immune
responses,
thereby
driving
carcinogenesis.
Altered
esophageal
microbiota,
characterized
reduced
beneficial
bacteria
increased
pathogenic
species,
further
exacerbate
local
growth.
Gut
also
affects
systemic
immunity,
influencing
chemotherapy
immunotherapy
certain
enhancing
or
inhibiting
treatment
responses.
Microbiota
composition
shows
potential
non-invasive
for
early
detection,
personalized
therapy.
Novel
strategies
targeting
microbiota—such
probiotics,
dietary
modifications,
fecal
transplantation—offer
promising
avenues
restore
balance
improve
potentially
patient
outcomes.
Integrating
microbiome-focused
into
current
frameworks
could
management,
reduce
adverse
effects,
enhance
survival.
These
findings
highlight
need
research
microbiota-tumor
microbial
interventions
transform
prevention,
particularly
cases
late-stage
diagnosis
response.
Journal of Cancer,
Journal Year:
2025,
Volume and Issue:
16(6), P. 1782 - 1793
Published: Feb. 18, 2025
Oncolytic
viral
therapy
is
a
promising
treatment
for
cancer,
where
'cold'
tumour
cells
can
become
'hot'
to
the
host
immune
system.
However,
with
few
FDA
approved
therapies,
development
of
new
strategies
more
cancer
types
has
been
slow
and
relatively
unsuccessful
in
recent
years,
Combination
successful
other
treatment,
therefore,
may
be
viable
alternative
improve
efficacy
oncolytic
which
reduce
some
adverse
events
currently
used
monotherapies,
virus
chemotherapy
being
mutually
complimentary
each
other.
Combining
viruses
checkpoint
inhibitors
provides
significant
increase
when
was
combined
drug
ipilimumab.
Phase
I
II
studies
concluded
that
combination
chemotherapies
safe
effective
but
did
not
significantly
on
current
monotherapies.
Recent
experiments
suggest
CAR-T
CAR--M
therapeutic
approach
needs
advance
clinical
testing
observe
human
response
therapy.
Viral
ipilimumab
showed
highest
potential
trials
should
advanced
phase
III
find
conclusive
supporting
evidence.
This
review
aims
identify
evaluate
evolving
advances
genetic
engineering
providing
enhanced
activity
tumour,
addressing
lack
responses
tumours,
an
additional
role
enhancing
conventional
therapies.
The
'turn
up
heat'
microenvironment
immunogenicity
anticancer
treatments,
future
Nanomedicine,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 13
Published: April 5, 2025
Nanotechnology
has
revolutionized
cancer
treatment
by
providing
innovative
solutions
through
nanocancer
therapies,
nanovaccines,
and
nanoparticles.
This
review
focuses
on
the
application
of
these
technologies
in
colorectal
(CRC),
highlighting
their
progression
from
preclinical
studies
to
clinical
trials.
Nanoparticles,
including
liposomes,
silica,
gold,
lipid
nanoparticles,
possess
unique
properties
that
enhance
drug
delivery,
improve
therapeutic
efficacy,
minimize
systemic
toxicity.
Additionally,
nanovaccines
are
being
developed
elicit
robust
immune
responses
against
CRC
cells.
paper
offers
a
comprehensive
overview
current
state
nanotechnology-based
treatments
for
CRC,
emphasizing
key
trials
demonstrate
potential.
Furthermore,
discusses
challenges
faced
this
field.
It
outlines
future
directions
research,
underscoring
need
ongoing
efforts
translate
promising
into
practical
applications.
Nanomedicine,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 18
Published: May 7, 2025
Cancer
immunotherapies
have
transformed
oncology
by
utilizing
the
immune
system
to
target
malignancies;
however,
limitations
in
efficacy
and
potential
side
effects
remain
significant
challenges.
Nanoparticles
shown
promise
enhancing
drug
delivery
improving
activation,
with
for
numerous
modifications
tailor
them
specific
environments
or
targets.
Integrating
nanoplatforms
offers
a
promising
avenue
overcome
these
hurdles,
treatment
outcomes
reducing
adverse
effects.
By
delivery,
targeting,
modulation,
can
unlock
full
of
cancer
immunotherapy.
This
review
explores
role
addressing
immunotherapy
outcomes,
examining
various
types
nanoplatforms.
Understanding
mechanisms
immunomodulation
through
nanoplatform
deliveries
is
crucial.
We
discuss
how
interact
tumor
microenvironment,
modulate
tumor-associated
macrophages
regulatory
T
cells,
activate
cells
directly,
enhance
antigen
presentation,
promote
immunological
memory.
Further
benefits
include
combination
approaches
integrating
chemotherapy,
radiotherapy,
phototherapy.
Immunotherapy
relatively
new
approach,
but
clinical
studies
already
utilize
nanoplatform-based
results.
aims
provide
insights
into
pave
way
more
effective
personalized
strategies.
